The pharmaceutical world is seeing a significant shift in diabetes management with the emergence of GLP-1 transdermal devices. These systems offer a potentially more user-friendly alternative to subcutaneous administrations of GLP-1 receptor agonists, lessening the requirement of daily needle pok